BRISBANE, Calif.--(BUSINESS WIRE)--May 31, 2016--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing CODIT™ (Characterized Oral Desensitization
ImmunoTherapy) treatments for life-threatening food
allergies, today announced that Stephen G. Dilly, M.B.B.S., Ph.D., Chief
Executive Officer of Aimmune, will present a company overview at two
upcoming investor conferences in June as follows:
Goldman Sachs 37th Annual Global Healthcare Conference on
Thursday, June 9, 2016, at 8:40 a.m. Pacific Time in Rancho Palos
JMP Securities Life Sciences Conference on Wednesday, June 22,
2016, at 11:30 a.m. Eastern Time in New York, New York
The live webcasts of the presentations will be accessible on the Events
page under the Investor Relations section of the Aimmune website at www.aimmune.com.
Archived replays of the webcasts will be available for approximately 30
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy
(CODIT™) system, an approach to oral immunotherapy (OIT), uses
rigorously characterized product candidates with gradual, controlled
up-dosing protocols to obtain clinically meaningful desensitization to
food allergens. Aimmune’s first CODIT product, AR101 for the treatment
of peanut allergy, has received the FDA’s Breakthrough Therapy
Designation for the desensitization of peanut-allergic patients 4-17
years of age. Aimmune’s Phase 3 trial of AR101, PALISADE, is now
enrolling patients. For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160531005359/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,